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and plasminogen activator inhibitor 1 are recently vali-
dated prognostic markers for lymph node-negative 
breast cancer patients and thus may be of value in select-
ing node-negative patients that do not require adjuvant 
chemotherapy. 
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 Introduction 
 Breast cancer accounts for approximately 35% of all 
cancers in Western females, with half the cases occurring 
in women less than 55 years old  [1] . Multiple factors are 
associated with increased breast cancer risk  [2–8] . While 
breast cancer incidence has increased over the last 30–40 
years, mortality has remained stable, probably refl ecting 
earlier diagnosis as well as improved treatment options 
 [9, 10] . The latter include surgery, radiotherapy, chemo-
therapy, hormonal therapy and immunotherapy. The ini-
tial treatment of localized primary breast cancer is given 
with curative intent and usually includes surgery and/or 
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 Abstract 
 Recommendations are presented for the routine clinical 
use of serum and tissue-based markers in the diagnosis 
and management of patients with breast cancer. Their 
low sensitivity and specifi city preclude the use of serum 
markers such as the MUC-1 mucin glycoproteins (CA 
15.3, BR 27.29) and carcinoembryonic antigen in the di-
agnosis of early breast cancer. However, serial measure-
ment of these markers can result in the early detection 
of recurrent disease as well as indicate the effi cacy of 
therapy. Of the tissue-based markers, measurement of 
estrogen and progesterone receptors is mandatory in 
the selection of patients for treatment with hormone 
therapy, while HER-2 is essential in selecting patients 
with advanced breast cancer for treatment with Her-
ceptin (trastuzumab). Urokinase plasminogen activator 
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radiotherapy. In recent years, the prognosis for patients 
with breast cancer has improved due to the administra-
tion of adjuvant hormonal therapy and adjuvant chemo-
therapy  [11, 12] . Currently, in the developed world, over 
70% of patients with a diagnosis of breast cancer survive 
5 years or more  [13, 14] . 
 Rational administration of these expensive and fre-
quently unpleasant treatments requires identifi cation 
both of those patients with localized disease at most risk 
of recurrence and those who have distant metastases or 
micrometastases which are unlikely to respond to local 
therapies  [15, 16] . Therefore, objective methods for as-
sessing response to treatment in patients receiving such 
therapies are highly desirable. In this article, we consider 
how the measurement of tumor markers in serum and 
tissue can best contribute to this assessment, presenting 
the recommendations of the European Group on Tumor 
Markers (EGTM) ( table 1 ), and where appropriate com-
paring these markers with those of other expert panels 
 [17, 18] . 
 Serum Tumor Markers 
 Numerous serum tumor markers have been described 
for breast cancer, including members of the MUC-1 
family of mucin glycoproteins (e.g., CA 15.3, BR 27.29, 
MCA, CA 549), carcinoembryonic antigen (CEA), on-
coproteins (e.g., HER-2/c-erbB-2) and cytokeratins (e.g., 
tissue polypeptide antigen and tissue polypeptide-spe-
cifi c antigen)  [19–24] . Members of the MUC-1 family 
are the most widely used serum tumor markers in breast 
cancer, but as they have similar diagnostic sensitivities 
and specifi cities, the use of more than one MUC-1 anti-
gen is unlikely to confer any advantage  [19, 20, 25] . 
However, CEA measurement can provide additional 
complementary information. For this reason, the com-
bination of one MUC-1 marker and CEA is the recom-
mended serum marker panel in patients with breast
cancer. 
 Screening and Diagnosis 
 Their lack of organ and tumor specifi city and low sen-
sitivity, particularly in early-stage disease, generally in-
validate the use of tumor markers for either screening or 
early diagnosis  [17, 22] . Low levels of tumor markers in 
patients with suspected breast cancer never exclude the 
presence of malignancy. Nevertheless, tumor marker de-
termination may complement patient staging: high levels 
of CA 15.3 (e.g.  1 50 U/ml) and/or CEA (e.g.  1 20 ng/ml) 
Table 1. Serum markers in breast cancer: EGTM recommenda-
tions
Serum markers
The most useful serum markers for breast cancer are CA 15.3 (or 
BR 27.29) and CEA, but due to their low sensitivity, they cannot 
be recommended for screening or early diagnosis, but serial levels 
may be useful in the early diagnosis of distant metastases.
Prognosis: Preoperatively elevated levels of either CA 15.3 or CEA 
are associated with adverse outcome in patients with breast cancer; 
their use in combination with established prognostic factors is rec-
ommended.
Early diagnosis of recurrence: Serial CA 15.3 and CEA serum de-
terminations are recommended for the early detection of recur-
rence in patients with breast cancer and no evidence of disease, if 
the detection of recurrent or metastatic disease would alter clinical 
management. The impact of this lead time information on patient 
outcome is not clear.
Therapy monitoring: Markers should be measured prior to every 
chemotherapy course and at least every 3 months for patients re-
ceiving hormone therapy.
The EGTM regards an increase in tumor marker concentration of 
at least 25% of the previous value – with the second value above 
the reference interval – to be signifi cant. It is recommended that 
such an increase be confi rmed with a second specimen obtained 
within a month. If the continued increase is confi rmed, this pro-
vides evidence of progressive disease. Similarly, confi rmed de-
creases in serum levels of more than 50% are consistent with tumor 
response.
Technical aspects: Well-documented and relevant IQC and EQA 
procedures must be in place and should be followed whenever tu-
mor markers are measured. If it is necessary to change method dur-
ing serial monitoring, this must be undertaken with considerable 
care.
Tissue markers
ER and PR should be assayed on all newly diagnosed breast cancer 
patients. The primary use of steroid receptors is for selecting pa-
tients for treatment with hormone therapy.
HER-2 should be used for selecting patients with advanced breast 
cancer for treatment with Herceptin and for identifying patients 
with early breast cancer for participation in clinical trials involving 
adjuvant Herceptin. HER-2 may also be of use for identifying pa-
tients who are particularly likely to benefi t from adjuvant anthra-
cycline-based chemotherapy.
HER-2 should not be used to predict response to either hormone, 
CMF or taxane therapy.
For determining HER-2 status, immunohistochemistry (calibrated 
against FISH) should be employed. For samples with an immuno-
histochemistry score of 2+, confi rmation by FISH should be carried 
out.
uPA and PAI-1, determined by a validated ELISA, may be used for 
determining prognosis, especially in patients with lymph node-neg-
ative disease.
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in patients thought to have localized disease suggest the 
presence of unsuspected metastatic disease. 
 The sensitivity of tumor markers is signifi cantly high-
er in patients with advanced disease  [21, 26–38] and is 
related to the site of recurrence  [18, 30, 39] . CA 15.3 and 
CEA are not useful in the early diagnosis of locoregional 
recurrence, for which clinical examination is superior. 
However, abnormal CEA and CA 15.3 levels are found 
in 40–50 and 50–70% of patients with distant metastases 
 [40–43] . Simultaneous use of both markers allows early 
diagnosis of metastases (mainly in bone and liver) in up 
to 60–80% of patients with breast cancer. By using com-
binations of several markers (e.g., CA 15.3, CEA and cy-
tokeratins), it is possible to increase the sensitivity to at 
least 90% in patients with distant metastases  [24, 33, 34, 
44–46] . 
 EGTM Recommendation 
 The most useful serum markers for breast cancer are 
CA 15.3 (or BR 27.29) and CEA, but due to their low 
sensitivity, they cannot be recommended for screening or 
early diagnosis. 
 Prognosis 
 Serum levels of CA 15.3 (and other MUC-1 glycopro-
teins) and CEA are related to tumor burden, with signifi -
cantly higher values in patients with nodal involvement 
or large tumors  [18, 26–28, 47] . Several studies have dem-
onstrated shorter disease-free survival and overall sur-
vival in patients with high preoperative levels of these 
markers, while others reported confl icting data  [18–20, 
27–29, 48–52] . Most studies with large patient groups 
and long follow-up times conclude that preoperative se-
rum CA 15.3 and CEA concentrations are independent 
prognostic factors  [28, 29, 50–55] . However, it has not 
yet been demonstrated if the use of tumor markers as in-
dicators of recurrence can lead to improvement in either 
patient disease-free survival or overall survival. 
 EGTM Recommendation 
 Preoperatively elevated levels of either CA 15.3 or CEA 
are associated with adverse outcome in patients with breast 
cancer, and the EGTM recommends their measurement 
in combination with established prognostic factors . 
 Early Detection of Recurrence 
 The main reasons for monitoring patients following 
treatment for primary breast cancer are to enable the 
early detection of new primary or locally recurrent can-
cers that may be cured by early intervention, as well as 
the early detection of metastatic disease. The sensitivity 
of tumor markers for detecting recurrent disease is clear-
ly related to the site of recurrence  [40–43] . As previ-
ously described, low sensitivity precludes the use of tu-
mor markers in the early diagnosis of locoregional recur-
rence, but serial tumor marker measurements can 
contribute usefully to early diagnosis of distant meta-
static disease, especially in liver and bone. Increases in 
MUC-1 serum markers reportedly provide the fi rst in-
dication of recurrence, prior to clinical or radiological 
indication (e.g., by chest X-ray, liver ultrasonography, 
bone scans), in 40–55% of treated patients  [40–42, 56] . 
Additional CEA measurement can increase the sensitiv-
ity in the early detection of recurrence obtained with CA 
15.3 by up to 5–25% of the patients  [40] . Reported lead 
times vary from 2 to 18 months (mean 5.2)  [30–32, 40–
43, 55–62] . 
 The specifi city of markers for the detection of recur-
rence in the follow-up of patients with no clinical evi-
dence of disease is related to the marker cut-off points 
used  [30–32, 40–43, 56–58, 60–64] . In one study, the 
proportion of false-positive results (abnormal values 
without recurrence) was 5% for CEA and 6.5% for CA 
15.3 using cut-off values of 5   g/l and 35 U/ml, respec-
tively  [40] . Using higher cut-off values (CEA 10   g/l, CA 
15.3 60 U/ml) and at least two serial increases ( 1 15%), 
specifi city increased to almost 100%  [41, 58] . Using the 
latter criteria, sensitivities of 45 and 30% have been re-
ported for CA 15.3 and CEA, respectively, with an in-
crease in either tumor marker providing the fi rst sign of 
recurrence in 60–70% of patients  [41, 42] . 
 Early detection of metastasis has two different aims: 
one is the diagnosis, and the second, the possibility to 
earlier initiate systemic treatment. There is a controversy 
as to whether intensive screening incurs extra expenses 
and whether it unnecessarily increases anxiety; addition-
ally, its value is uncertain regarding ultimate outcome 
 [64, 65] . Other diagnostic tools such as chest radiography, 
bone scans and liver ultrasonograms are useful in the di-
agnosis of recurrent or metastatic disease but do not seem 
to increase survival  [66–68] . In spite of the previously 
reported studies, the basic hypothesis that early diagnosis 
of recurrences may prolong survival is supported by the 
observation that smaller breast tumors generally are more 
likely to respond to therapy than larger tumors. The in-
verse relationship between tumor mass and chemothera-
py response means that in more advanced metastatic dis-
ease, response to treatment is generally shorter and less 
likely  [69] . 
 Molina  et al.
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 EGTM Recommendation 
 The EGTM recommends serial CA 15.3 and CEA se-
rum determinations for the early detection of recurrence 
in patients with breast cancer and no evidence of disease, 
if the detection of recurrent or metastatic disease would 
alter clinical management, although the impact of this 
lead time information on patient outcome is not clear. 
Currently, there are no data available regarding the opti-
mum frequency for the measurement of serum tumor 
markers in the early diagnosis of recurrent disease. How-
ever, the EGTM panel suggests the following approach 
during the follow-up of asymptomatic women: tumor 
markers should be determined every 2–4 months (accord-
ing to the risk of recurrence) during the initial 5 years 
after diagnosis, then every 6 months during the next 3 
years and at yearly intervals thereafter. 
 Therapy Monitoring 
 The most important clinical application of tumor 
markers in metastatic breast cancer lies in monitoring 
response to therapy. Patients in remission usually have 
decreasing marker levels, while those with progressive 
disease generally have increasing levels  [33, 35, 37, 38, 
44, 45, 70–72] . Studies comparing tumor marker moni-
toring with conventional International Unit against Can-
cer criteria vary considerably – both in terms of the dis-
ease status of included patients and the criteria for mark-
er assessment – but most authors conclude that the 
measurement of tumor markers provides an objective 
means of guiding therapy  [33–36, 57–63, 70–76] . 
 Frequency of Measurement 
 It depends on the treatment how frequently markers 
should be measured. The EGTM recommends that tumor 
markers in patients treated with chemotherapy should be 
determined before every chemotherapy course. In pa-
tients treated with hormone therapy, they should be mea-
sured at least every 3 months. 
 Defi ning Signifi cant Changes 
 There is little agreement in the literature about what 
constitutes a clinically signifi cant change in marker level. 
The EGTM regards an increase in tumor marker concen-
tration of at least 25% of the previous value – with the 
second value above the reference interval – to be signifi -
cant, recommending that such an increase be confi rmed 
in a second specimen obtained within a month. If the 
continued increase is confi rmed, this provides evidence 
of progressive disease. Similarly, confi rmed decreases in 
serum levels of more than 50% are consistent with tumor 
response, to avoid the intraindiviual as well as the inter-
assay variability  [33–35, 46, 77–79] . Certain treatments 
may cause transient increases in serum marker levels, so 
that increases observed shortly after treatment must al-
ways be confi rmed. 
 Advantages of Tumor Marker Monitoring 
 Monitoring with tumor markers has been shown to be 
superior to monitoring by conventional International 
Unit against Cancer criteria in a number of studies  [33–
35, 46, 77–83] . Biochemical changes often precede clin-
ical or radiological signs of response or progression, po-
tentially enabling earlier treatment decisions regarding 
 continuation of effective therapy, discontinuation of in-
effective therapy, change of therapy or more effective 
palliation. It has been suggested that biochemical assess-
ment may result in cost savings of at least 50% when 
compared with assessment by clinical or radiological cri-
teria, which often require expensive imaging techniques 
such as computer tomography scans  [82] . However, 
whether this monitoring leads to enhanced survival or 
better quality of life remains to be determined  [83, 84] . 
 EGTM Recommendation 
 Markers should be measured prior to every chemo-
therapy course and at least every 3 months for patients 
receiving hormone therapy. Objective criteria for assess-
ing changes in markers should be in place and increases 
or decreases confi rmed appropriately. 
 Measurement of Serum Markers 
 Analytical requirements for tumor markers are similar 
to those for most other clinical analytes: the correct and 
appropriate specimen should be analyzed by a method 
which meets defi ned quality requirements for both inter-
nal quality control (IQC) and external quality assessment 
(EQA)   [85] . 
 Tumor marker assays from different manufacturers 
can give signifi cantly different results for the same serum 
 [86–88] . The method used should therefore be stated on 
the laboratory report. When it is necessary to change the 
method used to monitor a patient during follow-up, this 
should be undertaken with considerable care, e.g., by as-
saying a specimen using both methods for a period of 
time, so as to minimize the risk of misinterpretation of 
trends in marker levels. 
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 EGTM Recommendation 
 Well-documented and relevant IQC and EQA proce-
dures must be in place and should be followed whenever 
tumor markers are measured. If it is necessary to change 
the method during serial monitoring, this must be under-
taken with considerable care. 
 Tissue Markers 
 While serum markers in breast cancer are mostly used 
for monitoring patients with diagnosed disease, tissue-
based markers are primarily measured in order to deter-
mine prognosis and predict response to therapy. Clini-
cally, the most useful tissue-based markers in breast can-
cer are estrogen receptor (ER), progesterone receptor 
(PR) and HER-2 (also known as c-erbB-2 or neu).  Al-
though not yet in widespread clinical use, urokinase plas-
minogen activator (uPA) and plasminogen activator in-
hibitor 1 (PAI-1) are potential markers for determining 
prognosis in lymph node-negative breast cancer pa-
tients. 
 ER and PR 
 ER and PR are transcriptional factors which mediate 
the actions of estrogens and progesterone, respectively 
 [89, 90] . Both receptors are now known to exist in two dif-
ferent forms. For ER, these forms are known as ER-alpha 
and ER-beta  [91] , and for PR, the two forms are known 
as PRA and PRB  [92] . To date, for ER, a clinical role has 
only been established for the alpha form. Existing assays 
for PR do not discriminate between the two forms. 
 The main clinical application of ER (i.e. ER-alpha) 
and PR in breast cancer is selecting patients likely to re-
spond to hormone therapy. In both early and advanced 
disease, hormone receptor-positive patients have a sig-
nifi cantly greater probability of responding to hormone 
therapy than patients lacking receptors  [93–95] . There-
fore, the EGTM panel recommends that ER (i.e. ER-al-
pha) and PR assays be performed on all patients with 
newly diagnosed breast cancer. Similar recommenda-
tions have been previously made by the EGTM  [26, 96] , 
as well as by other expert panels such as the American 
Society of Clinical Oncology (ASCO)  [17, 97] , the Na-
tional Academy of Clinical Biochemistry  [96] , the Euro-
pean Society of Medical Oncology  [98] , the European So-
ciety of Mastology  [99] and a National Institute of Health 
developmental panel  [100] . At this stage, the assay of ER-
beta cannot be recommended for predicting response to 
endocrine therapy. 
 While the primary purpose for performing hormone 
receptor assays lies in selecting a likely response to endo-
crine therapy, information on receptor status or concen-
tration may also be of prognostic value. Generally, for the 
fi rst 4–5 years after diagnosis, ER-positive patients have 
a better outcome than ER-negative patients  [101, 102] . 
However, after this period, the favorable prognostic im-
pact of ER is lost. A further limitation of ER as a prog-
nostic factor is that it is of little value in lymph node-
negative patients  [101, 102] . Although less work has been 
carried out on the prognostic impact of PR, patients with 
tumors expressing PR also tend to have a better prognosis 
than those lacking this receptor  [95, 103] . 
 Measurement of ER and PR 
 Three well-established assays exist for measuring hor-
mone receptors, namely ligand binding, ELISA and im-
munohistochemistry. It is important to state that all the 
early studies showing a clinical utility for hormone recep-
tors were performed with ligand-binding assays. How-
ever, more recently, immunohistochemistry has largely 
replaced the older biochemical assays for determining re-
ceptor levels. Immunohistochemistry is simpler to per-
form than either ligand-binding assays or ELISA and has 
the distinct advantage of being the only assay that can be 
used for small tumors. Furthermore, at least for ER, im-
munohistochemistry assays have been shown to perform 
as well as the ligand-binding assays for predicting re-
sponse to hormone therapy  [104–110] . Therefore, for the 
present, the EGTM recommends that immunohisto-
chemistry should be used to determine hormone recep-
tors in breast cancers. 
 For immunohistochemistry, some of the most widely 
validated antibodies include 6F11 MAb or antibody ID5 
for ER  [104, 105, 111, 112] and antibodies PR88 KD68 
MAb or MAb 1294 for PR  [105, 111–113] . Scoring of 
immunohistochemical stain may be based on either per-
centage of cells stained or a combination of percentage of 
cells stained plus intensity of stain  [111, 112] . The hor-
mone receptor report should indicate this semi-quantita-
tive score, rather than merely stating a negative or posi-
tive fi nding  [111, 112] . 
 A new approach, using a combination of DNA fl ow 
cytometry and immunophenotyping on single cell sus-
pensions from formalin-fi xed paraffi n-embedded tissue, 
has the advantage of both objective quantitation and ap-
plication to small amounts of tissue. Furthermore, the 
quality of the DNA histograms serves as an internal con-
trol for the preservation of receptor proteins. Although 
this is a novel method for the quantitative determination 
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of markers in tissue and has been subjected to several 
studies  [114, 115] , it has not yet found wide acceptance, 
since a possible improved correlation with clinical out-
come has not yet been documented. 
 EGTM Recommendations 
 An assay of hormone receptors (i.e. ER and PR) is 
mandatory in the selection of patients with both early and 
advanced breast cancer for treatment with hormone ther-
apy. Patients with hormone receptor-positive tumors 
should be treated with some form of endocrine therapy, 
while receptor-negative patients should receive an alter-
nate form of therapy. 
 Immunohistochemistry with validated antibodies 
should be used to determine hormone receptors in breast 
cancer. 
 Since both ER and PR are relatively weak prognostic 
factors in breast cancer, these factors should not be used 
alone for differentiating between patients with indolent 
and aggressive breast cancers. However, hormone recep-
tors may be combined with established prognostic factors 
in determining outcome . 
 HER-2 
 HER-2, which is also known as c-erbB-2 or neu, en-
codes a transmembrane protein belonging to the epider-
mal growth factor receptor family [for a review, see ref. 
 116] . The HER-2 gene is either amplifi ed or overexpressed 
in 15–30% of invasive breast cancers. Amplifi cation of the 
HER-2 gene means that instead of having only 2 copies of 
the gene per cell, there may be 50–100 gene copies per cell. 
The number of HER-2 proteins per cell can then increase 
from 20,000–50,000 to as high as 2 million  [117] . 
 HER-2 has a number of potential uses in breast cancer, 
including determining prognosis, predicting relative re-
sistance to both hormone therapy and adjuvant cyclo-
phosphamide, methotrexate, 5-fl uorouracil (CMF) ther-
apy, selecting for enhanced response to adjuvant anthra-
cycline-based therapy and identifying patients for 
treatment with Herceptin (trastuzumab). The role of 
HER-2 in these specifi c areas is now briefl y discussed. 
 Predicting Response to Herceptin 
 Currently, the primary and only mandatory reason for 
determining HER-2 levels in breast cancer lies in select-
ing patients with advanced breast cancer for treatment 
with Herceptin (trastuzumab). Herceptin is a humanized 
MAb that binds with high affi nity to the extracellular do-
main of HER-2, thereby blocking its role in signal trans-
duction  [118] . Herceptin, alone or in combination with 
chemotherapy, is now widely used for the treatment of 
HER-2-positive patients with advanced breast cancer. 
Furthermore, Herceptin is currently being evaluated in 
clinical trials for the adjuvant treatment of HER-2-posi-
tive breast cancer  [119] . 
 Based on cell culture and animal model experiments 
 [117, 118] , it is generally believed and highly likely that 
overexpression of HER-2 is necessary for Herceptin to 
induce tumor regression. Consequently, at this stage, 
Herceptin should only be administered to breast cancer 
patients showing either gene amplifi cation or overexpres-
sion of HER-2. In agreement with the ASCO expert pan-
el  [97] , the EGTM panel recommends an assay of HER-2 
for selecting patients with advanced breast cancer for 
treatment with Herceptin. 
 Predicting Resistance to Endocrine Therapy 
 Most but not all published reports conclude that over-
expression of HER-2 is associated with relative resistance 
to hormone therapy in patients with breast cancer [for 
reviews, see ref.  120, 121] . Most of these studies have 
methodological limitations including a retrospective as-
say of HER-2, the use of different HER-2 assays and in-
clusion of relatively small numbers of patients. Further-
more, different forms of hormone therapy were used and 
different subgroups of patients were studied in the differ-
ent trials. Based on present information, the EGTM pan-
el is unable to recommend an assay of HER-2 for selecting 
endocrine resistance in patients with breast cancer. The 
ASCO  [97] and National Institute of Health panel  [100] 
have made similar recommendations. 
 Predicting Response to Chemotherapy 
 Similar to the situation with hormone therapy, contro-
versy also exists on the relationship between HER-2 and 
response to adjuvant CMF. Although most studies con-
clude that patients with HER-2-positive tumors derive 
less benefi t from adjuvant CMF than patients with HER-
2-negative cancers, there are again confl icting reports [for 
reviews, see ref.  120, 121] . In general, studies on the re-
lationship between HER-2 and response to CMF suffer 
from the same limitations as discussed above for endo-
crine therapy. Based on current fi ndings, the EGTM pan-
el, in agreement with the ASCO panel  [97] , is unable to 
recommended assay of HER-2 for predicting response to 
adjuvant CMF. 
 Although overexpression of HER-2 may be associated 
with relative resistance to adjuvant CMF, a number of 
retrospective studies suggest that increased levels of this 
oncoprotein predicts an enhanced response from anthra-
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cycline-based adjuvant therapy [for reviews, see ref.  120, 
121] . Indeed, the ASCO panel stated ‘that high levels of 
HER-2 may identify patients who particularly benefi t 
from anthracycline-based adjuvant therapy but that lev-
els of HER-2 should not be used to exclude patients from 
anthracycline treatment’  [97] . The EGTM panel supports 
this statement. 
 Compared with the response to CMF or anthracycline-
based therapy, relatively few studies have investigated 
the interaction between HER-2 and the benefi t of tax-
anes. While some reports concluded that patients with 
HER-2-positive tumors exhibited higher response rates 
to taxanes in advanced breast cancer than those with 
HER-2-negative cancers  [122] , others were unable to con-
fi rm these fi ndings  [123, 124] . In a recent retrospective 
study, Konecny et al.  [125] reported that patients with 
HER-2-positive tumors had a greater objective response 
than patients with HER-2-negative tumors to treatment 
with epirubicin/paclitaxel when used as fi rst-line chemo-
therapy for metastatic breast cancer. However, HER-2 
was not associated with response to epirubicin/cyclophos-
phamide. Despite these promising fi ndings, HER-2 can-
not, at present, be recommended in selecting for response 
or resistance to taxanes  [97] . 
 Determining Prognosis 
 Most published reports on axillary node-positive 
breast cancer patients conclude that either HER-2 gene 
amplifi cation or overexpression correlates with an ad-
verse outcome in patients with breast cancer [for a review, 
see ref.  126] . However, the prognostic impact of HER-2 
in node-negative breast cancer patients is less clear  [126] . 
It is important to point out that most of the studies relat-
ing HER-2 to patient outcome were retrospective in de-
sign, contained relatively low numbers of patients and 
used a variety of HER-2 assays. Furthermore, in many of 
the studies, patients received different types of adjuvant 
therapy, making it diffi cult to differentiate a prognostic 
from a predictive impact. Based on the available informa-
tion, the EGTM panel recommends that HER-2 should 
not be used alone for determining outcome in patients 
with breast cancer. However, as HER-2 is being measured 
on an increasing number of patients with breast cancer, 
information on HER-2 status may be combined with 
standard prognostic factors for determining outcome in 
patients with breast cancer. 
 Measurement of HER-2 
 Although multiple methods have been used to measure 
HER-2 gene amplifi cation/protein overexpression in 
breast tumors, the two most widely employed methods 
are immunohistochemistry and fl uorescent in situ hy-
bridization (FISH). The advantages of immunohisto-
chemistry include its wide availability, simplicity and 
relatively low costs. Its disadvantages include subjec-
tivity in evaluating the staining score, possible loss of 
HER-2 protein as a result of tissue storage and fi xation 
and variable results depending on both the antibody and 
staining procedure used. 
 In contrast to immunohistochemistry, FISH can theo-
retically provide a more objective scoring system. It also 
has the advantage of a built-in internal control consisting 
of two HER-2 gene copies in the non-malignant cells 
within the specimen. The disadvantages of FISH include 
its high costs, the requirement for a fl uorescent micro-
scope and the inability to preserve the slide for storage 
and review. In addition, reading the fl uorescent signal in 
a suffi ciently large number of cells for reliable individual 
scoring is diffi cult. 
 To avoid fading of the fl uorescent signal, chromogen-
ic in situ hybridization may be used. However, this ap-
proach is also unable to solve the problem relating to the 
limited number of cells that can be evaluated. Chromo-
genic in situ hybridization remains to be validated in pro-
spective studies. As regards monitoring the quality of the 
preservation of HER-2 protein during tissue fi xation and 
embedding, see above for ER. Combining the DNA his-
togram as a quality control aspect of tissue preservation 
with the specifi c quantifi cation of HER-2 in the epithe-
lial compartment by multiparametric analysis can be an 
alternative  [127] . 
 EGTM Recommendation 
 HER-2 should be assayed in order to select patients 
with advanced breast cancer for treatment with Her-
ceptin. However, at present, HER-2 is not recommended 
for predicting response to adjuvant CMF, taxanes or en-
docrine therapy in patients with breast cancer. 
 HER-2 should not be used alone for determining out-
come in patients with breast cancer. However, HER-2 
may be combined with other prognostic factors for pre-
dicting patient outcome. 
 For determining the HER-2 status in breast cancer, 
immunohistochemistry (calibrated against FISH) should 
be employed. For samples with an immunohistochemis-
try score of 2+, confi rmation by FISH should be carried 
out. 
 Molina  et al.
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 uPA and PAI-1 
 uPA is a serine protease implicated in cancer growth, 
invasion and metastasis [for a review, see ref.  128] .  PAI-1 
is an endogenous inhibitor of uPA, but paradoxically is 
also involved in tumor progression  [128] . Multiple 
 single institutional studies have shown that both uPA 
and PAI-1 are potent and independent prognostic fac-
tors in breast cancer  [129, 130] . This prognostic impact 
of uPA and PAI-1 has been shown in both lymph node-
negative and lymph node-positive breast cancer pa-
tients. Recently, the prognostic impact of uPA and PAI-1 
in lymph node-negative breast cancer patients was vali-
dated in both a randomized prospective trial and a pooled 
analysis (n  1 8,000 patients) of single institution studies 
 [131, 132] . 
 At present, the main use of these factors lies in select-
ing lymph node-negative patients who do not need or are 
unlikely to benefi t from adjuvant chemotherapy. Patients 
with low levels of both these proteins are at a relatively 
low risk of developing recurrent or metastatic disease 
and, consequently, may be able to avoid the toxic side ef-
fects and costs of adjuvant chemotherapy. 
 uPA and PAI-1 should be determined by ELISAs that 
have undergone both technical  [133, 134] and clinical 
validation  [131, 132] . For the determination of uPA and 
PAI-1 by ELISA, a small piece of breast tumor must be 
rapidly frozen in liquid nitrogen following histopatho-
logical examination. Recently, a microassay (i.e. a micro 
ELISA) was described for the measurement of uPA and 
PAI-1  [135, 136] . Although not yet clinically validated, 
this assay showed that uPA and PAI-1 levels in core bi-
opsies correlated well with corresponding levels in surgi-
cally removed tissue. Although multiple studies have de-
scribed the use of immunohistochemistry to detect uPA 
and PAI-1 in breast cancer, none have shown a signifi cant 
correlation with either ELISA values or patient outcome. 
Thus, at present, immunohistochemistry cannot be rec-
ommended for the clinical determination of uPA and 
PAI-1 in breast cancer. 
 EGTM Recommendation 
 According to the EGTM panel, uPA and PAI-1 may be 
used for determining prognosis in breast cancer, especially 
in the group of patients with lymph node-negative disease. 
ELISAs validated for both analytical and clinical perfor-
mance should be used for determining these proteins. 
 Gene Expression Profi ling 
 Instead of measuring individual markers, the use of 
DNA microarray or gene expression profi ling is a popular 
current research approach for determining prognosis. 
With a microarray, the expression of tens of thousands of 
genes (e.g., in a sample) can be determined simultane-
ously. In recent years, a number of investigators have 
shown that microarray techniques can predict outcome 
in patients with breast cancer  [137–141] . 
 In one of these studies, using this technique on lymph 
node-negative breast cancer patients, van’t Veer et al. 
 [137] identifi ed a 70-gene signature that correctly pre-
dicted the later appearance or absence of clinical me-
tastasis in 65/78 lymph node-negative patients. The ap-
plication of this prognostic classifi er to an independent 
set of 19 breast cancers resulted in only two incorrect 
classifi cations. 
 The 70-gene expression profi le was more recently val-
idated in a series of 295 consecutive breast cancer pa-
tients  [138] . In this larger study, the probability of re-
maining free of distant metastasis at 10 years after surgery 
was 85.2% in the patients with the good prognostic signa-
ture and 50.6% in those with the poor signature. The es-
timated hazard ratio for distant metastasis in the patients 
with the poor prognostic signature as compared with the 
group with the good prognostic signature was 5.1 (95% 
confi dence intervals 2.9–9.0; p  ! 0.001). A similar sig-
nifi cant difference in outcome between patients with the 
good and poor signature was seen in patients with either 
lymph node-negative or lymph node-positive patients. 
Multivariate analysis showed that the gene signature was 
an independent factor in predicting disease outcome. Al-
though these results with DNA microarray are promising, 
this technology is technically demanding, time-consum-
ing and expensive. Before clinical use, this technology 
must be simplifi ed, standardized and evaluated in exter-
nal quality assessment schemes. Furthermore, these pre-
liminary results must be confi rmed in a large prospective 
study or a meta-analysis/pooled analysis of individual 
studies. 
 Rather than using large numbers of genes, Paik et al. 
 [142] recently identifi ed a 21-gene panel (16 test genes 
and 5 reference genes) that predicted breast cancer recur-
rence in 668 lymph node-negative ER-positive patients 
that received adjuvant tamoxifen therapy. Using multi-
variate analysis, the gene panel predicted the outcome 
independently of patient age and tumor size. Important-
ly, the authors were able to carry out RT-PCR on RNA 
extracted from formalin-fi xed and paraffi n-embedded tis-
sue. However, as with the gene microarray results dis-
cussed above, these fi ndings require validation in inde-
pendent laboratories. 
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 EGTM Recommendation 
 Although initial results are promising, DNA microar-
ray should not be used at present for predicting outcome 
in patients with breast cancer. 
 Other Tissue-Based Markers 
 Based on available evidence, a routine assay of other 
breast cancer tissue markers, such as p53, c-myc, cathep-
sin B, cathepsin D, S phase or ploidy  [98, 134] , cannot be 
recommended at present. 
 Conclusions 
 MUC-1 antigen and CEA are the most useful serum 
markers in patients with breast cancer. Serial determina-
tion of these markers may be useful in routine therapy 
monitoring and for early detection of recurrence and pro-
gression during follow-up. However, interpretation of se-
quential measurements is a task for specialists who are 
able to integrate information at a multidisciplinary level 
in collaboration with the end users, general practitioners, 
surgeons and oncologists. Steroid receptors and HER-2 
are the tissue-based markers accepted in clinical practice, 
having an established role in predicting hormone sensi-
tivity or in Herceptin treatment, respectively. uPA and 
PAI-1 are recently validated as prognostic factors for 
lymph node-negative breast cancer patients and thus may 
be of use in selecting those node-negative patients who 
may not need to receive adjuvant chemotherapy. Other 
potential markers for breast cancer such as p53, cathepsin 
B, cathepsin D, S phase and ploidy look promising, but 
further research is necessary before their clinical utility is 
established. 
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